Latest & greatest articles for anastrozole

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on anastrozole or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on anastrozole and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for anastrozole

21. Cost-utility of adjuvant hormone therapies with aromatase inhibitors in post-menopausal women with breast cancer: upfront anastrozole, sequential tamoxifen-exemestane and extended tamoxifen-letrozole

Cost-utility of adjuvant hormone therapies with aromatase inhibitors in post-menopausal women with breast cancer: upfront anastrozole, sequential tamoxifen-exemestane and extended tamoxifen-letrozole Cost-utility of adjuvant hormone therapies with aromatase inhibitors in post-menopausal women with breast cancer: upfront anastrozole, sequential tamoxifen-exemestane and extended tamoxifen-letrozole Cost-utility of adjuvant hormone therapies with aromatase inhibitors in post-menopausal women (...) with breast cancer: upfront anastrozole, sequential tamoxifen-exemestane and extended tamoxifen-letrozole Skedgel C, Rayson D, Dewar R, Younis T Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined three adjuvant hormonal

2007 NHS Economic Evaluation Database.

22. Cost-effectiveness analysis of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: the 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen alone or in combination) trial Full Text available with Trip Pro

Cost-effectiveness analysis of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: the 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen alone or in combination) trial Cost-effectiveness analysis of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: the 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen alone or in combination) trial Cost-effectiveness analysis (...) of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: the 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen alone or in combination) trial Mansel R, Locker G, Fallowfield L, Benedict A, Jones D Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment

2007 NHS Economic Evaluation Database.

23. Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective - the 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen Al

Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective - the 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen Al Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective - the 5-year completed treatment analysis of the ATAC ('Arimidex (...) ', Tamoxifen Alone or in Combination) trial Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective - the 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen Alone or in Combination) trial Locker GY, Mansel R, Cella D, Dobrez D, Sorensen S, Gandhi SK Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each

2007 NHS Economic Evaluation Database.

24. Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis

Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2006 DARE.

25. Aromatase inhibitors (anastrozole, letrozole and examestane) for adjuvant therapy in early breast cancer

Aromatase inhibitors (anastrozole, letrozole and examestane) for adjuvant therapy in early breast cancer Aromatase inhibitors (anastrozole, letrozole and examestane) for adjuvant therapy in early breast cancer Aromatase inhibitors (anastrozole, letrozole and examestane) for adjuvant therapy in early breast cancer Augustovski F, Pichon Riviere A, Alcaraz A, Bardach A, Garcia Marti S, Lopez A, Glujovsky D, Regueiro A Record Status This is a bibliographic record of a published health technology (...) assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Augustovski F, Pichon Riviere A, Alcaraz A, Bardach A, Garcia Marti S, Lopez A, Glujovsky D, Regueiro A. Aromatase inhibitors (anastrozole, letrozole and examestane) for adjuvant therapy in early breast cancer. Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Informe de Respuesta Rapida No.63. 2006 Authors' objectives This report is intended

2006 Health Technology Assessment (HTA) Database.

26. Pharmacoeconomic aspects of adjuvant anastrozole or tamoxifen in breast cancer: a Slovenian perspective Full Text available with Trip Pro

, Cufer T, Borstnar S, Mrhar A. Pharmacoeconomic aspects of adjuvant anastrozole or tamoxifen in breast cancer: a Slovenian perspective. Anti-Cancer Drugs 2006; 17(6): 719-724 PubMedID DOI Other publications of related interest The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists’ Group. Anastrozole alone or in combination with tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002;359:2131-9. Hillner (...) Pharmacoeconomic aspects of adjuvant anastrozole or tamoxifen in breast cancer: a Slovenian perspective Pharmacoeconomic aspects of adjuvant anastrozole or tamoxifen in breast cancer: a Slovenian perspective Pharmacoeconomic aspects of adjuvant anastrozole or tamoxifen in breast cancer: a Slovenian perspective Piskur P, Sonc M, Cufer T, Borstnar S, Mrhar A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains

2006 NHS Economic Evaluation Database.

27. Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed-treatment analysis

Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined the use of anastrozole (Arimidex) in the adjuvant treatment of hormone receptor-positive (HR+), postmenopausal early breast cancer (BC) patients. Anastrozole was compared (...) , these will be referenced in the text of the abstract and their bibliographic details recorded here for information. Hillner B. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer. Cancer 2004;101:1311-2. ATAC Trialists' Group. Results of the ATAC (Arimidex, tamoxifen alone or in combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365:60-2. Early Breast

2006 NHS Economic Evaluation Database.

28. Cost-effectiveness of anastrozole compared to tamoxifen in hormone receptor-positive early breast cancer: analysis based on the ATAC trial Full Text available with Trip Pro

not reported. Cost results The cumulative 20-year breast cancer costs were EUR 37,827 in the anastrozole group and EUR 36,332 in the tamoxifen group. Therefore, the incremental cost of anastrozole was EUR 1,495. Synthesis of costs and benefits Anastrozole had an incremental cost-effectiveness ratio of EUR 4,233 per LY and EUR 3,958 per QALY gained. A sensitivity analysis exploring the use of a small pack of Arimidex showed costs of EUR 9,263 per LY gained and EUR 8,662 per QALY gained. The results were (...) Cost-effectiveness of anastrozole compared to tamoxifen in hormone receptor-positive early breast cancer: analysis based on the ATAC trial Cost-effectiveness of anastrozole compared to tamoxifen in hormone receptor-positive early breast cancer: analysis based on the ATAC trial Cost-effectiveness of anastrozole compared to tamoxifen in hormone receptor-positive early breast cancer: analysis based on the ATAC trial Moeremans K, Annemans L Record Status This is a critical abstract of an economic

2006 NHS Economic Evaluation Database.

29. Pharmacoeconomic analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with operable and estrogen receptor-positive breast cancer

Pharmacoeconomic analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with operable and estrogen receptor-positive breast cancer Pharmacoeconomic analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with operable and estrogen receptor-positive breast cancer Pharmacoeconomic analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women (...) therapy with aromatase inhibitors or with tamoxifen in postmenopausal women with operable breast cancer. The authors concluded that exemestane after tamoxifen was more cost-effective than anastrozole or letrozole. The quality of the methodology used was satisfactory. Both the results and methods were adequately reported. As there was no head-to-head comparison of the three aromatase inhibitors, caution should be exercised when evaluating which one was the most cost-effective. Type of economic

2006 NHS Economic Evaluation Database.

30. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. (Abstract)

Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Tamoxifen has been the standard adjuvant treatment for postmenopausal women with hormone-responsive early breast cancer for more than 20 years. However, the third-generation aromatase inhibitor anastrozole has proven efficacy and tolerability benefits compared with tamoxifen when used as initial adjuvant therapy (...) . We investigate whether women who have received a period of adjuvant tamoxifen would benefit from being switched to anastrozole.We present a combined analysis of data from two prospective, multicentre, randomised, open-label trials with nearly identical inclusion criteria. Postmenopausal women with hormone-sensitive early breast cancer who had completed 2 years' adjuvant oral tamoxifen (20 or 30 mg daily) were randomised to receive 1 mg oral anastrozole (n=1618) or 20 or 30 mg tamoxifen (n=1606

2005 Lancet

31. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer Full Text available with Trip Pro

tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer. Cancer 2004; 101(6): 1311-1322 PubMedID DOI Other publications of related interest Baum M, Buzdar A, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003;98 (...) Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor

2004 NHS Economic Evaluation Database.

32. Cost-effectiveness of anastrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer

Simons W R, Jones D, Buzdar A. Cost-effectiveness of anastrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer. Clinical Therapeutics 2003; 25(11): 2972-2987 PubMedID Other publications of related interest Nabholtz JM, Buzdar A, Pollak M, et al. Anastrozole is superior to tamoxifen as first line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomised trial. Arimidex Study Group. Journal of Clinical (...) Oncology 2000;18:3758-67. Bonneterre J, Thurlmann B, Robertson JF, et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomised Group Efficacy and Tolerability study. Journal of Clinical Oncology 2000;18:3748-57. Glasziou PP, Cole BF, Gelber R, et al. Quality adjusted survival analysis with repeated quality of life measures. Statistics in Medicine 1998;17:1215-29. Indexing Status Subject indexing

2003 NHS Economic Evaluation Database.

33. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. (Abstract)

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. In the adjuvant setting, tamoxifen is the established treatment for postmenopausal women with hormone-sensitive breast cancer. However, it is associated with several side-effects including endometrial cancer and thromboembolic disorders. We aimed to compare the safety and efficacy outcomes of tamoxifen (...) with those of anastrozole alone and the combination of anastrozole plus tamoxifen for 5 years.Participants were postmenopausal patients with invasive operable breast cancer who had completed primary therapy and were eligible to receive adjuvant hormonal therapy. The primary endpoints were disease-free survival and occurrence of adverse events. Analysis for efficacy was by intention to treat.9366 patients were recruited, of whom 3125 were randomly assigned anastrozole, 3116 tamoxifen, and 3125 combination

2002 Lancet Controlled trial quality: predicted high

34. Anastrozole: a review of its use in the management of postmenopausal women with advanced breast cancer

Anastrozole: a review of its use in the management of postmenopausal women with advanced breast cancer Anastrozole: a review of its use in the management of postmenopausal women with advanced breast cancer Anastrozole: a review of its use in the management of postmenopausal women with advanced breast cancer Wiseman L R, Adkins J C Authors' objectives To examine the use of anastrozole in the management of postmenopausal women with advanced breast cancer. Searching Medical literature published (...) since 1966 on anastrozole was identified using AdisBase, MEDLINE and EMBASE. References also identified from reference lists of published articles. Bibliographic information, including contributory data was also requested from the company developing the drug. Search terms: anastrozole, armidex, ic-d-1033, zd-1033 (all databases), breast cancer, aromatase inhibitor (AdisBase only), 120511-73-1 (MEDLINE and EMBASE only). Searches last updated 1 September 1988. Study selection Study designs

1998 DARE.